Navigation Links
PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting

ATLANTA, Dec. 6 /PRNewswire/ -- Data from 11 PROCRIT(R) (Epoetin alfa) studies will be presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition December 8 - 11, 2007.
The data will provide important insights including:

-- the potential impact on the nation's blood supply of limiting the use

of erythropoiesis-stimulating agents (ESAs) for the treatment of

chemotherapy-induced anemia (CIA);

-- the use of PROCRIT in extended dosing regimens;

-- the use of PROCRIT for treatment of transfusion-dependent anemia in

patients with myelodysplastic syndromes (MDS);

-- PROCRIT and real-world practice patterns;

-- PROCRIT in managed care settings; and

-- observational data from the Dosing Outcomes Study of Erythropoiesis-

Stimulating Therapies (DOSE) Registry.

In some cases, the data are from investigational studies and do not reflect current U.S. Food and Drug Administration (FDA)-approved PROCRIT indications or recommended dosage and administration. Please note that all information presented at ASH is embargoed for media release until the data are made available to the public on the ASH Web site.

Data on the Potential Impact on Blood Supply of Limiting ESA Use for Chemotherapy Patients

-- Poster: Impact of Limiting Erythropoiesis-Stimulating Agent Use for

Chemotherapy-Induced Anemia on the United States Blood Supply

Francis Vekeman, M.A., Groupe d'analyse, Ltee, Montreal, Quebec, Canada

Presentation: Monday, December 10, 2007; 5:00pm - 7:00pm; Hall B3 and

B4 in the Georgia World Congress Center (Poster Board Number 115,

Publication Number 2896)

A modeling simulation was employed to estimate the impact of limiting

the use of ESAs for CIA on the U.S. blood supply. The model used a

top-down approach to compare the number of red blood cell units

transfused in ESA-treated patients to the number of red blood cell

units that would be transfused if ESAs were discontinued or limited in

the same population.

Data on PROCRIT Investigational Extended Dosing Regimens

-- Abstract: Early vs. Standard Intervention With an Extended Epoetin alfa

(EPO) Dose Regimen of 120,000 Units (U) Every 3 Weeks (Q3W) in

Chemotherapy (CT)-Induced Anemia: Results for Elderly vs. Younger

Patients in a Randomized Clinical Trial

Veena Charu, M.D., Pacific Cancer Medical Center, Inc., Anaheim, CA

Publication Number 3769

A retrospective subset analysis of a prospective, randomized, open-

label, multi-center study compared key efficacy and safety results of

elderly (n=62) and younger (n=73) patients with non-myeloid malignancy.

Patients with chemotherapy planned for greater than or equal to 9 weeks

and baseline hemoglobin greater than or equal to 11 and less than or

equal to 12 grams per deciliter (g/dL) were randomized either to

"early" intervention with Epoetin alfa or to "standard" intervention

with Epoetin alfa when hemoglobin decreased to <11 g/dL.

-- Abstract: Erythroid Response to Epoetin alfa (EPO) 120,000 Units (U)

Every Three Weeks (Q3W) Initiated Early or at a Standard Threshold in

Chemotherapy-Induced Anemia (CIA)

Veena Charu, M.D., Pacific Cancer Medical Center, Inc., Anaheim, CA

Publication Number 3770

A retrospective analysis of observed hematologic profiles from a 16-

week, open-label, randomized study enrolled patients with non-myeloid

malignancy, baseline hemoglobin greater than or equal to 11 and less

than or equal to 12 g/dL, and chemotherapy planned for greater than or

equal to 9 weeks to evaluate whether hemoglobin levels could be

adequately maintained with Q3W Epoetin alfa initiation treatment.

Patients were randomized according to study protocol to "early" or

"standard" intervention groups (n=68 in each group).

-- Abstract: Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4

Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer

Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final


Daniel Shasha, M.D., Beth Israel Medical Center, New York, NY

Publication Number 3775

This prospective, randomized, open-label, multi-center pilot study with

100 patients with an active non-myeloid malignancy, baseline hemoglobin

level less than or equal to 11 g/dL, and not receiving or planning to

receive CT or RT during the course of the study, was designed to

investigate two novel dosing regimens in this population. Based on

recent safety concerns from studies with another ESA in cancer patients

not receiving CT or RT, enrollment in this study was stopped prior to

the planned enrollment.

Data on PROCRIT for the Investigational Treatment of Transfusion-Dependent Anemia in MDS Patients

-- Poster: Treatment of MDS Related Transfusion-Dependent Anemia With

Epoetin alfa: A Meta-Analysis Perspective

Suneel Mundle, Ph.D., Ortho Biotech Clinical Affairs, LLC, Bridgewater,


Presentation: Saturday, December 8, 2007; 5:30pm - 7:30pm; Hall B3 and

B4 in the Georgia World Congress Center (Poster Board Number 625,

Publication Number 1471)

A meta-analysis of data extracted from studies found in PubMed,

American Society of Clinical Oncology (ASCO) and ASH proceedings from

1990 to 2006 in transfusion-dependent MDS patients (n=578) treated with

Epoetin alfa plus or minus granulocyte and granulocyte-macrophage

colony stimulating factors (G/GM-CSF) assessed the efficacy of Epoetin

alfa in achieving transfusion independence in transfusion-dependent MDS


-- Abstract: Drug Utilization and Cost Considerations of Erythropoiesis-

Stimulating Agents in Patients with Myelodysplastic Syndromes

Francois Laliberte, M.A., Groupe d'analyse, Ltee, Montreal, Quebec,


Publication Number 4611

A retrospective analysis of medical claims examined Epoetin alfa and

darbepoetin alfa dosing patterns, ESA treatment costs and red blood

cell transfusion use in order to characterize real-world utilization of

ESAs in adult patients with MDS.

-- Abstract: Assessment of Epoetin alfa in Patients with Myelodysplastic

Syndrome Utilizing an Electronic Medical Record Database

Bruce Feinberg, D.O., Georgia Cancer Center Oncology, Decatur, GA

Publication Number 5180

A retrospective, observational study, using electronic medical record

data from a large oncology/hematology practice in the southeastern

United States, was conducted to gain a better understanding of the

demographics, real-world treatment patterns and clinical outcomes for

patients with MDS receiving Epoetin alfa.

Data on PROCRIT and Real-World Practice Patterns

-- Poster: Erythropoiesis-Stimulating Agents for Chemotherapy Induced

Anemia: Analysis of an Electronic Medical Record Database within a

Large Oncology/Hematology Practice

Bruce Feinberg, D.O., Georgia Cancer Center Oncology, Decatur, GA

Presentation: Saturday, December 8, 2007; 5:30pm - 7:30pm, Hall B3 and

B4 in the Georgia World Congress Center (Poster Board Number 117,

Publication Number 963)

A retrospective, observational study using electronic medical record

data from a large oncology/hematology practice in the southeastern

United States was conducted to gain a better understanding of real-

world treatment patterns and clinical outcomes in patients with cancer

receiving chemotherapy and ESA therapy.

Data on PROCRIT in Managed Care Settings

-- Abstract: Drug Utilization Patterns and Cost Considerations for

Erythropoiesis Stimulating Agents in Cancer Chemotherapy Patients in a

Managed Care Setting

Alyson Mandel, Ph.D., Medical Practice Data Corporation, Claverack, NY

Publication Number 5157

A retrospective, observational analysis of ESA utilization in more than

4,100 chemotherapy patients using adjudicated medical claims between

2004 and 2006 from seven health plans was conducted to understand

current utilization patterns. The study examined real-world dosing and

drug costs for ESAs (Epoetin alfa and darbepoetin alfa) in cancer

patients receiving chemotherapy.

-- Abstract: Medical Visit Patterns in Cancer Chemotherapy Patients

Receiving Erythropoiesis Stimulating Agents in a Managed Care Setting

Alyson Mandel, Ph.D., Medical Practice Data Corporation, Claverack, NY

Publication Number 5156

A retrospective analysis of medical claims between January 2004 and

December 2005 using the Integrated Health Care Information Systems

national database and representing more than 35 health plans was

conducted to describe visit patterns and identify the proportion of

medical visits made exclusively for ESA treatment in cancer

chemotherapy patients.

Observational Data from the DOSE Registry

-- Abstract: Hemoglobin Levels Prior To Blood Transfusions In Oncology

Patients Receiving Chemotherapy and Erythropoiesis-Stimulating Agents

(ESAs): Observational Data from the DOSE Registry

Kay Larholt, Sc.D., Abt Associates, Lexington, MA

Publication Number 4019

A retrospective analysis of real-world data from ESA-treated oncology

patients obtained from an ongoing prospective, observational registry,

Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies

(DOSE), to characterize hemoglobin levels or transfusion triggers.

Data were collected from participating hospital- and community-based

outpatient practices between December 2003 and July 2007.

About PROCRIT (Epoetin alfa)

PROCRIT is used for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and those who are not on dialysis, who are being treated with zidovudine for HIV infection, and to reduce the need for transfusion in anemic patients who are scheduled for elective noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ.

Important U.S. Safety Information for PROCRIT


Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.


-- ESAs shortened overall survival and/or time-to-tumor progression in

clinical studies in patients with advanced breast, head and neck,

lymphoid, and non-small cell lung malignancies when dosed to target a

hemoglobin of greater than or equal to 12 g/dL.

-- The risks of shortened survival and tumor progression have not been

excluded when ESAs are dosed to target a hemoglobin of < 12 g/dL.

-- To minimize these risks, as well as the risk of serious cardio- and

thrombovascular events, use the lowest dose needed to avoid red blood

cell transfusions.

-- Use only for treatment of anemia due to concomitant myelosuppressive


-- Discontinue following the completion of a chemotherapy course.

Perisurgery: PROCRIT increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.


PROCRIT is contraindicated in patients with uncontrolled hypertension or with known hypersensitivity to albumin (human) or mammalian cell-derived products.

Additional Important Safety Information

-- The dose of PROCRIT should be titrated for each patient to achieve and

maintain the following hemoglobin levels:

-- Chronic renal failure patients -- hemoglobin levels between 10

to 12 g/dL. If a patient does not attain hemoglobin levels of 10

to 12 g/dL despite 12 weeks of appropriate PROCRIT therapy, see



-- Cancer or HIV patients -- the lowest hemoglobin level sufficient

to avoid transfusion and not to exceed 12 g/dL.

-- Monitor hemoglobin regularly during therapy, more frequently

following a dosage adjustment or until hemoglobin becomes stable.

-- Cases of pure red cell aplasia (PRCA) and of severe anemia, with

or without other cytopenias, associated with neutralizing antibodies to

erythropoietin have been reported in patients with chronic renal

failure receiving PROCRIT by subcutaneous administration. If any

patient develops a sudden loss of response to PROCRIT, accompanied by

severe anemia and low reticulocyte count, and anti-erythropoietin

antibody-associated anemia is suspected, withhold PROCRIT and other

erythropoietic proteins. Contact ORTHO BIOTECH (1-888-2ASKOBI or

1-888-227-5624) to perform assays for binding and neutralizing

antibodies. If erythropoietin antibody-mediated anemia is confirmed,

PROCRIT should be permanently discontinued and patients should not be

switched to other erythropoietic proteins.

-- The safety and efficacy of PROCRIT therapy have not been established

in patients with a known history of a seizure disorder or underlying

hematologic disease (e.g., sickle cell anemia, myelodysplastic

syndromes or hypercoagulable disorders).

-- In some female patients, menses have resumed following PROCRIT therapy;

the possibility of pregnancy should be discussed and the need for

contraception evaluated.

-- Prior to and regularly during PROCRIT therapy monitor iron status;

transferrin saturation should be greater than or equal to 20% and

ferritin should be greater than or equal to 100 ng/mL. During therapy

absolute or functional iron deficiency may develop and all patients

will eventually require supplemental iron to adequately support

erythropoiesis stimulated by PROCRIT.

-- During PROCRIT therapy, blood pressure should be monitored carefully

and aggressively managed, particularly in patients with an underlying

history of hypertension or cardiovascular disease.

-- In studies, the most common side effects included fever (pyrexia),

diarrhea, nausea, vomiting, swelling of hands or feet (edema), lack or

loss of strength or weakness (asthenia, fatigue), shortness of breath,

high blood pressure, headache, joint pain (arthralgias), abnormal skin

sensations (as tingling or tickling or itching or burning;

paresthesia), rash, constipation and upper respiratory infection.

Please visit for the full Prescribing Information, including the Boxed WARNINGS.

About Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
(Date:11/25/2015)... total global healthcare industry is expected to grow at a ... has the highest projected growth at 12.7%, and ... ), is second with growth projected at 11.5%. ... In 2013-2014, total government funded healthcare was nearly 68%. Federal ... in 2013-2014. In real terms, out of pocket expenditure increased ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers ... on mammography, according to a study published online in the journal Radiology. Researchers ... mammography may necessitate a change in treatment. , Breast MRI is the most ...
(Date:11/25/2015)... ... 25, 2015 , ... TyloHelo Inc , North America’s ... Sauna accessories help improve the bather experience in the sauna, and the accessories ... the purist looking for simplicity in design to accessories that encourage a greater ...
Breaking Medicine News(10 mins):